Business Description
Edwards Lifesciences Corp
NAICS : 339113
SIC : 3842
ISIN : US28176E1082
Compare
Compare
Traded in other countries / regions
EWLS.AustriaE1WL34.BrazilEWL.GermanyEW.MexicoEW.Switzerland0REN.UKEW.USA IPO Date
2000-04-03Description
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. Its key products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.82 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | 0.36 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 14.68 | |||||
| Beneish M-Score | -2.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.1 | |||||
| 3-Year EBITDA Growth Rate | 15.5 | |||||
| 3-Year EPS without NRI Growth Rate | 14.2 | |||||
| 3-Year FCF Growth Rate | 2.4 | |||||
| 3-Year Book Growth Rate | 13 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 5.89 | |||||
| Future 3-5Y Total Revenue Growth Rate | 9.53 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.7 | |||||
| 9-Day RSI | 44.04 | |||||
| 14-Day RSI | 45.12 | |||||
| 6-1 Month Momentum % | 19.85 | |||||
| 12-1 Month Momentum % | -5.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.01 | |||||
| Quick Ratio | 2.17 | |||||
| Cash Ratio | 1.16 | |||||
| Days Inventory | 264.12 | |||||
| Days Sales Outstanding | 43.15 | |||||
| Days Payable | 56.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.81 | |||||
| Operating Margin % | 32.34 | |||||
| Net Margin % | 27.07 | |||||
| ROE % | 24.99 | |||||
| ROA % | 17.55 | |||||
| ROIC % | 24.11 | |||||
| ROC (Joel Greenblatt) % | 71.17 | |||||
| ROCE % | 23.69 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 34.9 | |||||
| Forward PE Ratio | 32.92 | |||||
| PE Ratio without NRI | 34.9 | |||||
| Shiller PE Ratio | 53.23 | |||||
| Price-to-Owner-Earnings | 67.04 | |||||
| PEG Ratio | 2.31 | |||||
| PS Ratio | 9.44 | |||||
| PB Ratio | 8.53 | |||||
| Price-to-Tangible-Book | 12.07 | |||||
| Price-to-Free-Cash-Flow | 52.93 | |||||
| Price-to-Operating-Cash-Flow | 42.08 | |||||
| EV-to-EBIT | 28.34 | |||||
| EV-to-Forward-EBIT | 28.95 | |||||
| EV-to-EBITDA | 26.27 | |||||
| EV-to-Forward-EBITDA | 26.19 | |||||
| EV-to-Revenue | 9.15 | |||||
| EV-to-Forward-Revenue | 8.46 | |||||
| EV-to-FCF | 51.08 | |||||
| Price-to-Projected-FCF | 2.87 | |||||
| Price-to-DCF (Earnings Based) | 1.3 | |||||
| Price-to-DCF (FCF Based) | 2.38 | |||||
| Price-to-Median-PS-Value | 1.07 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.05 | |||||
| Price-to-Graham-Number | 4.33 | |||||
| Price-to-Net-Current-Asset-Value | 87.6 | |||||
| Earnings Yield (Greenblatt) % | 3.53 | |||||
| Forward Rate of Return (Yacktman) % | 18.75 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:EW
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Edwards Lifesciences Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5,500.8 | ||
| EPS (TTM) ($) | 2.41 | ||
| Beta | 1.12 | ||
| Volatility % | 24.03 | ||
| 14-Day RSI | 45.12 | ||
| 14-Day ATR ($) | 1.766533 | ||
| 20-Day SMA ($) | 85.5015 | ||
| 12-1 Month Momentum % | -5.28 | ||
| 52-Week Range ($) | 67.13 - 107.92 | ||
| Shares Outstanding (Mil) | 606.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Edwards Lifesciences Corp Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Edwards Lifesciences Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Edwards Lifesciences Corp Frequently Asked Questions
What is Edwards Lifesciences Corp(EW)'s stock price today?
The current price of EW is $84.10. The 52 week high of EW is $107.92 and 52 week low is $67.13.
When is next earnings date of Edwards Lifesciences Corp(EW)?
The next earnings date of Edwards Lifesciences Corp(EW) is 2023-07-28 Est..
Does Edwards Lifesciences Corp(EW) pay dividends? If so, how much?
Edwards Lifesciences Corp(EW) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers